Mild Cognitive Impairment Clinical Trial
— SUPERBRAINOfficial title:
A Multicenter Randomized Controlled Study to Evaluate the Efficacy of a 24-week Multidomain Intervention Via Face-to-face and Video Communication Platforms in Mild Cognitive Impairment
This study will be done to investigate the effectiveness of a 24-week multidomain intervention program consisting of cognitive training, exercise, nutrition management, vascular disease risk factor management, social activity, and motivational enhancement on the cognitive function compared to the control group in mild cognitive impairment.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | July 2023 |
Est. primary completion date | June 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 79 Years |
Eligibility | Inclusion Criteria: - 60 to 79 years of age - Having at least one modifiable dementia risk factor - Complaints of cognitive decline by a participant or informant - A performance score that is lower than 1.0 standard deviations below the age-, and education-adjusted normative means for one or more of the delayed recall, naming, visuoconstruction, attention, and executive function tests - MMSE Z score = - 1.5 - Independent activities of daily living - Being able to use the tablet PC through education, or having a person who can help a participant use the tablet PC. - Having a reliable informant who could provide investigators with the requested information - Provide written informed consent Exclusion Criteria: - Major psychiatric illness such as major depressive disorders - Dementia - Other neurodegenerative disease (e.g., Parkinson's disease) - Malignancy within 5 years - Cardiac stent or revascularization within 1 year - Serious or unstable symptomatic cardiovascular disease - Other serious or unstable medical disease such as acute or severe asthma, active gastric ulcer, severe liver disease, or severe renal disease - Severe loss of vision, hearing, or communicative disability - Any conditions preventing cooperation as judged by the study physician - Significant laboratory abnormality that may result in cognitive impairment - Illiteracy - Unable to participate in exercise program safely - Coincident participation in any other intervention trial |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Dong-A University Hospital | Busan | |
Korea, Republic of | Chonnam University Hospital | Gwangju | |
Korea, Republic of | Inha University Hospital | Incheon | |
Korea, Republic of | Bobath Memorial Hospital | Seongnam | |
Korea, Republic of | Ewha Womans Seoul Hospital | Seoul | |
Korea, Republic of | Konkuk University Hospital | Seoul | |
Korea, Republic of | Ajou University Hospital | Suwon |
Lead Sponsor | Collaborator |
---|---|
Inha University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of cognition | Repeatable Battery for the Assessment of Neuropsychological Status (range 40-160). Higher scores indicate better performance. | Change from Baseline at 24 weeks | |
Secondary | Change of global cognition | Mini-Mental State Examination (range 0-30). Higher scores indicate better performance. | Change from Baseline at 24 weeks | |
Secondary | Change of function | Clinical Dementia Rating scale-Sum of Boxes (range 0-18). Higher scores indicate worse performance. | Change from Baseline at 24 weeks | |
Secondary | Change of subjective memory | Prospective and Retrospective Memory Questionnaire (range 16-80). Higher scores indicate worse performance. | Change from Baseline at 24 weeks | |
Secondary | Change of depression | Geriatric Depression Scale-15 items (range 0-15). Higher scores indicate worse performance. | Change from Baseline at 24 weeks | |
Secondary | Change of quality of life | Quality of life-Alzheimer's disease (range 0-52). Higher scores indicate better performance. | Change from Baseline at 24 weeks | |
Secondary | Change of activities of daily living | Bayer Activities of Daily Living (range 1-10). Higher scores indicate worse performance. | Change from Baseline at 24 weeks | |
Secondary | Change of nutritional behavior | Nutrition Quotient for elderly (range 0-100). Higher scores indicate better performance. | Change from Baseline at 24 weeks | |
Secondary | Change of nutrition | Mini Nutritional Assessment (range 0-14). Higher scores indicate better performance. | Change from Baseline at 24 weeks | |
Secondary | Change of motor function | Short Physical Performance Battery (range 0-12). Higher scores indicate better performance. | Change from Baseline at 24 weeks | |
Secondary | Change of sleep quality | Pittsburgh Sleep Quality Index (range 0-21). Higher scores indicate worse performance. | Change from Baseline at 24 weeks | |
Secondary | Change of motivation | Self Determination Index (SDI). Higher scores of SDI indicate better performance. | Change from Baseline at 24 weeks. Higher scores indicate better performance. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |